Matthew Brams - 06 Feb 2026 Form 4 Insider Report for Cingulate Inc. (CING)

Reporting relationship: EVP and Chief Medical Officer
Issuer ticker: CING
Reported as of: 06 Feb 2026
Net transaction value: +$9,963
SEC form: 4
Accepted by SEC: 10 Feb 2026, 19:00:19 UTC
Prior SEC filing: 09 Jul 2025
Next SEC filing: 11 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Shane J. Schaffer, Attorney-in-Fact

Key filing fact

Matthew Brams filed Form 4 for Cingulate Inc. (CING) on 10 Feb 2026.

Key facts

This page summarizes Matthew Brams's Form 4 filing for Cingulate Inc. (CING).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 Feb 2026, 19:00.

Change

Previous filing in this sequence was filed on 09 Jul 2025.
Current net transaction value: +$9,963.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001884361 Primary reporting owner

Brams Matthew

Relationship: EVP and Chief Medical Officer
Address: 1901 W. 47TH PLACE, KANSAS CITY
Signature: /s/ Shane J. Schaffer, Attorney-in-Fact
Signature date: 10 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CING transaction

Common Stock

Purchase

Transaction value: $9,808
Shares: +1,946
Change %: +72%
Price: $5.04
Shares after: 4,656
Date: 06 Feb 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CING transaction Derivative

Warrant to Purchase Common Stock

Purchase

Transaction value: $156
Shares: +1,556
Change %
Price: $0.1000
Shares after: 1,556
Date: 06 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,556
Exercise price: $5.04
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Common stock and warrants were acquired in the Issuer's private placement disclosed in the Current Report on Form 8-K filed with the SEC on January 28, 2026.

Footnote F2

The warrant is exercisable upon the Issuer obtaining stockholder approval of the private placement, as required by the Nasdaq rules. The expiration date of the warrant is 36 months after the exercise date.